Qvents

Shared Beta-Lactam Facilities: Achieving

Recent USFDA warning letter, issued to Baxter (October 2026), citing inadequate beta lactam contamination controls

FDA Warning Letter to Eurofins Flags Mic

USFDA has issued a Warning Letter to Eurofins SF Analytical Laboratories, Inc, Contract Testing Laboratory

CDSCO Guideline for Action on Spurious &

Amidst the heightened surveillance and enforcement actions initiated by different state licensing authorities (state FDAs)

FDA issues Guidance on Container Closure

The USFDA has released a new draft guidance, Container Closure Systems for Human Drugs and

Qvents Apps and Tools For QMS and GMP Pr

Qvents provides useful tools for QMS processes – Risk Assessments, Continuous Process Validations, Supply Chain Traceability

USFDA Warning letter to Intas Flags Inte

The USFDA recently issued a warning letter to Intas Pharmaceuticals Limited (Dehradun facility, FEI 3005890633

Unichem Recalls Hypertension Tablets for

Unichem Pharmaceuticals (USA), Inc. initiated a recall of Bisoprolol fumarate and Hydrochlorothiazide tablets in the

USFDA 483 to Pharmathen Flags Deficient

USFDA Inspection of Pharmathen’s Rodopi facility in Greece (FEI 3009961173) resulted in issuance of Form

Imprimis Recall Unapproved Ophthalmic In

Imprimis NJOF recalled three intraocular ophthalmic injection drug products in December 2025 (as per USFDA

Laboratory Incidents and Validation Fail

In November 2025, the USFDA issued a Warning Letter to Bangalore-based Cdymax India following an